Peter E. Schwartz, MD
Professor
Yale University School of Medicine
333 Cedar St.,
P.O. Box 208063 FMB 328
New Haven,
CT
USA
06520-8063
Biographical Sketch: Dr. Schwartz completed a fellowship in gynecologic oncology at the M.D.Anderson Cancer Center in 1975. He joined the faculty at Yale University where he rose up the academic ranks and has a chaired professorship. He established the Division of Gynecologic Oncology at Yale in 1978 and received approval for a board certified gynecologic oncology training program in 1980. He has been employing neoadjuvant chemotherapy (NACT) in the treatment of women with advanced stage ovarian cancer since 1979, first in medically compromised patients and later for those with very extensive disease in the upper abdomen unlikely by CT criteria to be optimally surgically cytoreduced and for patients with Stage IV disease. He has published extensively on the role of NACT in the treatment of advanced stage ovarian cancer."
Papers:
140
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
182
Cervical adenocarcinoma in situ: an institutional retrospective review of surgical management and outcome
262
Choice of adjuvant chemotherapy following neoadjuvant carboplatin/paclitaxel and delayed primary debulking
356
Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations
401
Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma